CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...

Nurix Therapeutics, Inc. has announced the enrollment of the first patient in its Phase 1b/2 clinical trial investigating bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader, in combination ...

Nurix Therapeutics, Inc. ( NRIX ), a clinical-stage biopharmaceutical company, announced on Wednesday that it has enrolled the first patient in a Phase 1b/2 study evaluating bexobrutideg in ...

A new study reports that the circadian clock gene BMAL1 and the cell cycle checkpoint regulator WEE1 are significantly ...

Vir Biotechnology Inc. has appointed David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, bringing more than... Read More ...

A new case report documents 127 days of persistent SARS-CoV-2 RNA positivity in a woman with chronic lymphocytic leukaemia, ...

Eli Lilly (LLY) valuation review: obesity drugs fuel growth, but upside looks limited with ~8.5% IRR. Read here for a ...

Nurix Therapeutics (NASDAQ:NRIX) enrolled the first patient in its Phase 1b/2 study evaluating bexobrutideg with venetoclax ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will ...

Curis shares covered USD 0.73 to USD 0.77 during the October 6 session, with volume of 182,514 shares. The 52-week range of ...